Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the pharmacokinetics, safety, and tolerability of a twice-daily fixed-dose combination of aclidinium bromide/formoterol fumara…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide/formoterol fumarate fixed-dose combination (Aclidinium bromide/formoterol fumarate)

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2019-07-22